Editas Medicine Inc. to Showcase Preclinical Gene Editing Advances at ASGCT Annual Meeting
Editas Medicine Inc., a pioneering gene editing company, is set to attend the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting in New Orleans, LA, from May 13-17, 2025. At the event, the company plans to share in vivo preclinical data demonstrating the use of targeted lipid nanoparticles to deliver HBG1/2 promoter editing cargo to hematopoietic stem and progenitor cells. Additionally, Editas will present proof of concept for using in vivo CRISPR editing to upregulate a target liver protein and reduce a disease-associated biomarker.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Editas Medicine Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001650664-25-000071), on May 12, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。